Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00854100 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Cariprazine As Adjunctive Therapy In Major Depressive Disorder
A Phase 2 study, sponsored by Forest Laboratories.
- Completed
- Registry status
- Phase 2
- Development phase
- 231
- Enrollment target
NCT00854100 is a Phase 2 study that has completed, run by Forest Laboratories. The registered enrollment target is 231 participants.
The verdict
NCT00854100, a Phase 2 study, has completed, sponsored by Forest Laboratories.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 231 participants
- Enrollment target
Study Summary
This is an outpatient study to evaluate the safety, and efficacy of RGH-188 as an add-on therapy to standard antidepressants in patients who did not respond to previous antidepressant therapy.
Interventions
- DRUG Antidepressant + placebo
- DRUG Antidepressant + cariprazine (0.1-0.3 mg/day)
- DRUG Antidepressant + cariprazine (1-2 mg/d)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 231 participants |
| Start Date | 2009-06-30 |
| Est. Completion | 2010-12-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00854100
The ClinicalTrials.gov registry entry for NCT00854100 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 231 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Forest Laboratories, which has 145 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Antidepressant + placebo is the first listed.
NCT00854100 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00854100 about?
NCT00854100 is a clinical study titled "Safety and Efficacy of Cariprazine As Adjunctive Therapy In Major Depressive Disorder". This is an outpatient study to evaluate the safety, and efficacy of RGH-188 as an add-on therapy to standard antidepressants in patients who did not respond to previous antidepressant therapy.
What is the current status of trial NCT00854100?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 231 participants. The study started on 2009-06-30. Estimated completion is 2010-12-06.
What interventions are being tested in trial NCT00854100?
The interventions under investigation include: Antidepressant + placebo (DRUG), Antidepressant + cariprazine (0.1-0.3 mg/day) (DRUG), Antidepressant + cariprazine (1-2 mg/d) (DRUG).
Who is sponsoring clinical trial NCT00854100?
This trial is sponsored by Forest Laboratories, which has 145 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.